7 June 2021

The development of novel technology for improved detection of clinically relevant chromosomal rearrangements in tumors

Researchers from the group of Oncode Investigator Wouter de Laat (Hubrecht Institute), in collaboration with biotech company Cergentis and lymphoma experts of 5 Dutch hospitals, developed a novel technology for improved detection of clinically relevant chromosomal rearrangements in tumors. The method, FFPE-TLC technology, promises to improve diagnostics for lymphoma and may also be relevant for rearrangement detection in other cancers such as sarcoma and lung- and prostate cancer. The study was published in Nature Communications on the 7th of June.

Bianca-Olivia Nita

Bianca-Olivia Nita

All cells in our body contain chromosomes, which carry our genetic material. When a change occurs in the organization of the chromosomes, this is called a chromosomal rearrangement. Such rearrangements can come in the form of a translocation, which means that part of a chromosome is transferred to another chromosome. Other examples of chromosomal rearrangements include deletions – part of the genetic material is absent – or duplications – part of the genetic material is doubled.

Clinical relevance

Some chromosomal rearrangements are clinically relevant: they can lead to genetic diseases or cancer. Lymphoma, cancer of the body’s lymphatic system, can originate from translocations or other chromosomal rearrangements. Detecting these clinically relevant genetic changes is important for proper diagnosis of lymphoma. Therefore, researchers from the group of Wouter de Laat, in collaboration with biotech company Cergentis and lymphoma experts of 5 Dutch hospitals, developed novel technology for improved detection of chromosomal rearrangements in lymphatic tumors.

Novel technology

The technology called FFPE-TLC allows the researchers to detect translocations and other chromosomal rearrangements in selected target genes with increased sensitivity and specificity. Additionally, they developed the PLIER algorithm, which automizes the detection of these changes in patients’ genetic material. Thereby, the researchers greatly improve lymphoma diagnostics.

Improved diagnostics

The study, published in Nature Communications, analyzes 149 tumor samples of patients with lymphoma and shows that FFPE-TLC has clear advantages over FISH – the currently most common used method for translocation detection. FFPE-TLC not only yields more information, it also shows a better sensitivity and higher resolution.

“The FFPE-TLC approach promises to improve lymphoma diagnostics and may also be relevant for the detection of chromosomal rearrangements in other types of cancer, such as sarcoma and lung- and prostate cancer. Our collaboration therefore brings the field a major step forward,” concludes Wouter de Laat, lead researcher on the project.

You can read the full article here.

Other News

PE 6
Eerste live bijeenkomst Oncode Patiënt Perspectief Programma brengt (ex-)patiënten en onderzoekers dichter bij elkaar
(Text in Dutch) Benieuwd hoe onderzoekers en (ex)patiënten elkaar kunnen helpen? Lees de highlights over Oncode's Patiënt Perspectief Programma meeting, waar onderzoekers en patiënt partners elkaar ontmoetten.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Figure nature option3
Specialized immune cells carry potential for new cancer immunotherapies
Oncode Investigators Emile Voest, Ton Schumacher and Lodewyk Wessels (all NKI), together with scientists from Leiden University Medical Center (LUMC) have discovered how specialized immune cells can detect and remove cancers that are ‘invisible’ to the conventional defense mechanisms of the immune system. The findings could lead to novel cancer immunotherapies. Their work is published today in Nature.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Image t cell recognize tumor cell
New technique to detect T cells that recognize a patient’s tumor
Oncode Investigators Emile Voest and Ton Schumacher together with Wouter Scheper (all NKI) have developed a new technique that can map out molecules on the tumor cells in individual cancer patients that are recognized by T cells. This new technology is an important step toward personalized immunotherapy. Their findings were published today in Nature Biotechnology.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>